By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The New England Journal of Medicine 

10 Shattuck Street

Boston  Massachusetts  02115-6094  U.S.A.
Phone: 617-734-9800 Fax: 617-739-9864


SEARCH JOBS


Industry
Services

Segment
Publisher





Company News
Amgen (AMGN) Release: Repatha (Evolocumab) Phase III Cognitive Function Study Results Published In The New England Journal of Medicine 8/17/2017 6:15:13 AM
Positive Phase III Results Of Genentech (RHHBY)’s Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In The New England Journal of Medicine 7/27/2017 7:42:44 AM
Chugai Pharma's Bispecific Antibody "Emicizumab" Global Phase III Data In Patients With Haemophilia A With Inhibitors Published In The New England Journal of Medicine Online 7/10/2017 6:47:57 AM
The New England Journal of Medicine Publishes Full Analysis Of Rydapt (Midostaurin) Phase III RATIFY Trial In Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) 6/26/2017 6:34:15 AM
Protein Sciences Corporation Release: Superior Protection By Flublok Influenza Vaccine In Seniors Documented In The New England Journal of Medicine 6/22/2017 9:15:27 AM
The New England Journal of Medicine Publishes Results From Aetion Real-World Data Analysis 6/21/2017 7:00:14 AM
Akcea Therapeutics Announces Publication In The New England Journal of Medicine Of Data With AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects 5/25/2017 9:19:12 AM
Akcea Therapeutics Announces Publication In The New England Journal of Medicine Of Data With AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects 5/25/2017 6:58:56 AM
Regeneron (REGN) Announces ANGPTL3/Evinacumab Publication In The New England Journal of Medicine And Positive Phase ll Data In People With HoFH 5/25/2017 6:53:51 AM
Pfizer (PFE) Release: Phase III OCTAVE Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal of Medicine 5/4/2017 6:48:42 AM
12345678910...
//-->